Media Release Entered into strategic collaboration with Dr. Reddy’s for commercialisation of eftilagimod alfa (efti) in all ...

Regeneron Pharmaceuticals, Inc. Fourth quarter 2025 revenues increased 3% to $3.9 billion versus fourth quarter 2024; full year 2025 revenues increased 1% to $14.3 billion versus ...

AMPLITUDE is the first clinical trial to evaluate potential therapies for patients with mHSPC and known HRR gene alterations, with positive results supporting the niraparib-based combination regimen ...

DelveInsight's TIGIT Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable ...

Media Release Entered into strategic collaboration with Dr. Reddy's for commercialisation of eftilagimod alfa (efti) in all countries outside North America, Europe, Japan, and Greater ChinaIn January ...

Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody and Moditope active immunotherapies to treat cancer, today announces a business ...

In the era of personalized oncology, implementation of reliable biomarkers with prognostic and predictive value is necessary, the latter being most ...

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, ...

Netskope, Inc. engages in the provision of cloud based security solutions. It offers business developing analytics for visibility, policy enforcement and other cloud solutions. Its products include ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.